Gline Matthew's most recent trade in Roivant Sciences Ltd was a trade of 10,945 Common Shares done at an average price of $11.0 . Disclosure was reported to the exchange on May 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.04 per share. | 20 May 2025 | 10,945 | 17,283,766 | - | 11.0 | 120,833 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.15 per share. | 20 Apr 2025 | 10,945 | 17,294,711 | - | 10.2 | 111,092 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. | 20 Mar 2025 | 10,945 | 17,305,656 | - | 11.0 | 120,067 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.72 per share. | 20 Feb 2025 | 10,945 | 17,316,601 | - | 10.7 | 117,330 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.15 per share. | 20 Jan 2025 | 11,623 | 17,327,546 | - | 11.1 | 129,596 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.57 per share. | 20 Dec 2024 | 10,945 | 17,339,169 | - | 11.6 | 126,634 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.49 per share. | 20 Nov 2024 | 10,945 | 17,350,114 | - | 11.5 | 125,758 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.92 per share. | 20 Oct 2024 | 10,945 | 17,361,059 | - | 11.9 | 130,464 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 11.79 per share. | 20 Sep 2024 | 1,983,257 | 17,870,543 | - | 11.8 | 23,382,600 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 1,550,000 | 14,973,184 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Sep 2024 | 1,550,000 | 19,853,800 | - | 3.9 | 5,967,500 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 11.97 per share. | 20 Sep 2024 | 498,539 | 17,372,004 | - | 12.0 | 5,967,512 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.97 per share. | 20 Sep 2024 | 10,945 | 18,303,800 | - | 12.0 | 131,012 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.48 per share. | 20 Aug 2024 | 10,947 | 18,314,745 | - | 11.5 | 125,672 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 14,450,000 | 18,325,692 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 2,754,821 | 3,875,692 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.00 per share. | 20 Jul 2024 | 10,945 | 1,120,871 | - | 11 | 120,395 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.80 per share. | 20 Jun 2024 | 10,945 | 1,131,816 | - | 10.8 | 118,206 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.37 per share. | 20 May 2024 | 10,945 | 1,142,761 | - | 11.4 | 124,445 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.46 per share. | 20 Apr 2024 | 10,945 | 1,153,706 | - | 10.5 | 114,485 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 994,373 | 0 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 390,579 | 1,380,642 | - | - | Common Shares | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.54 per share. | 30 Mar 2024 | 215,991 | 1,164,651 | - | 10.5 | 2,276,545 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 20 Mar 2024 | 10,945 | 990,063 | - | 10.0 | 109,559 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.54 per share. | 20 Feb 2024 | 10,945 | 1,001,008 | - | 11.5 | 126,305 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.35 per share. | 20 Jan 2024 | 10,945 | 1,011,953 | - | 10.4 | 113,281 | Common Shares |
| Roivant Sciences Ltd | Gline Matthew | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 85,232 | 994,373 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Gline Matthew | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 47,351 | 2,178,150 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 38,453 | 1,044,941 | - | - | Common Shares | |
| Roivant Sciences Ltd | Gline Matthew | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.58 per share. | 27 Dec 2023 | 22,043 | 1,022,898 | - | 11.6 | 255,258 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.96 per share. | 20 Dec 2023 | 10,945 | 1,006,488 | - | 10.0 | 109,012 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 28,410 | 1,193,247 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 12,088 | 1,051,732 | - | - | Common Shares | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 11.25 per share. | 29 Aug 2023 | 6,784 | 1,044,948 | - | 11.3 | 76,320 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 10.83 per share. | 22 Aug 2023 | 11,015 | 1,039,644 | - | 10.8 | 119,292 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 11.79 per share. | 02 Aug 2023 | 11,749 | 1,050,659 | - | 11.8 | 138,521 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2023 | 56,821 | 1,136,426 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2023 | 23,149 | 1,062,408 | - | - | Common Shares | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 10.99 per share. | 24 Jul 2023 | 11,146 | 1,039,259 | - | 11.0 | 122,495 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 10.01 per share. | 22 Jun 2023 | 10,863 | 1,050,405 | - | 10.0 | 108,739 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2023 | 170,464 | 1,193,247 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2023 | 53,281 | 1,091,534 | - | - | Common Shares | |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 9.09 per share. | 27 May 2023 | 30,266 | 1,061,268 | - | 9.1 | 275,118 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 9.58 per share. | 23 May 2023 | 18,972 | 1,038,253 | - | 9.6 | 181,752 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 20 Apr 2023 | 19,375 | 1,057,225 | - | 8.8 | 170,500 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 7.30 per share. | 23 Mar 2023 | 18,563 | 1,076,600 | - | 7.3 | 135,510 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 8.43 per share. | 22 Feb 2023 | 14,471 | 1,095,163 | - | 8.4 | 121,991 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 8.56 per share. | 24 Jan 2023 | 15,594 | 1,109,634 | - | 8.6 | 133,485 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 7.10 per share. | 23 Dec 2022 | 19,408 | 1,125,228 | - | 7.1 | 137,797 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Other type of transaction at price $ 5.00 per share. | 20 Nov 2022 | 19,373 | 1,144,636 | - | 5 | 96,865 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 4.40 per share. | 25 Oct 2022 | 19,276 | 1,164,009 | - | 4.4 | 84,814 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 3.07 per share. | 23 Sep 2022 | 21,053 | 1,183,285 | - | 3.1 | 64,633 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 3.71 per share. | 24 Aug 2022 | 20,009 | 1,204,338 | - | 3.7 | 74,233 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 4.33 per share. | 25 Jul 2022 | 20,455 | 1,224,347 | - | 4.3 | 88,570 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 4.34 per share. | 23 Jun 2022 | 19,855 | 1,244,802 | - | 4.3 | 86,171 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 3.70 per share. | 20 May 2022 | 139,791 | 1,264,657 | - | 3.7 | 517,227 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 25 Apr 2022 | 8,509 | 1,404,448 | - | 3.8 | 32,675 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 4.84 per share. | 30 Mar 2022 | 33,686 | 1,438,211 | - | 4.8 | 163,040 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.74 per share. | 30 Mar 2022 | 25,254 | 1,412,957 | - | 4.7 | 119,704 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 5.06 per share. | 25 Mar 2022 | 35,386 | 1,471,897 | - | 5.1 | 179,053 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 5.13 per share. | 18 Mar 2022 | 82,006 | 1,507,283 | - | 5.1 | 420,691 | Common Shares |
| Roivant Sciences Ltd | Matthew Gline | Director, CEO | Sale of securities on an exchange or to another person at price $ 5.52 per share. | 07 Mar 2022 | 92,324 | 1,589,289 | - | 5.5 | 509,628 | Common Shares |